MB-204

Marvel’s lead compound (MB-204) is a novel fluorinated derivative of Istradefylline, the only clinically approved adenosine A2a receptor antagonist used for the treatment of Parkinson’s disease.

However, Marvel is developing MB-204 for diseases other than Parkinson’s disease, specifically depression, Alzheimer’s Disease and liver fibrosis due to non-alcoholic steatohepatitis (NASH). Each disease area represents a multi-billion market with high, unmet medical need. By modifying a known approved drug with logical chemical changes, coupled with the potential to develop the drug for multiple unrelated diseases, Marvel believes it significantly de-risks its drug development efforts.

Emerging roles of dysregulated adenosine homeostasis in brain disorders with a specific focus on neurodegenerative diseases

Read full article here: https://pubmed.ncbi.nlm.nih.gov/34635103/

CD39-mediated ATP-adenosine signalling promotes hepatic stellate cell activation and alcoholic liver disease

Read full article here: https://pubmed.ncbi.nlm.nih.gov/34033815/

Proposed Development Timeline:

Q1:2023

Complete Phase 1/2 clinical trial of MB- 204 includes placebo and efficacy endpoints

Seek US exchange listing and partnership talks

Comparable public companies at similar stage:

Athira > $500M
Annovis > $250M

*Note: timelines may be subject to change.

Marvel Non-Hallucinogenic Neuroplasticity Program

Marvel has identified a series of related compounds that appear to be potent, fast acting, water soluble and orally available small tryptamine derivatives that have anti-depressive activity but no overt hallucinatory activity in pilot studies.

Corporate Presentation

Download >Download PDF